NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Recent Updates for Industries

User Rating: 4 / 5

Star ActiveStar ActiveStar ActiveStar ActiveStar Inactive
 

We’re Ready for #MedSafetyWeek – Are You? ⏱️
published on 2024-10-31


📆 Join Us Next Week for #MedSafetyWeek!
published on 2024-10-28


List of Renewal Approved Veterinary Products
published on 2024-10-16


[Updated] 17-Hydroxyprogesterone Caproate (17-OHPC): Cancellation of Product Registration and Product Recall
published on 2024-10-14


Biosimilar Approved
published on 2024-10-14


Paracetamol and Fixed Drug Eruption (FDE): Upward Trend of Reports Involving Paediatric Patients
published on 2024-10-10


New Products Approved
published on 2024-10-09


KENYATAAN MEDIA KEMENTERIAN KESIHATAN MALAYSIA 8 OKTOBER 2024 - KELULUSAN PENDAFTARAN BAGI PRODUK SEMULA JADI DENGAN TUNTUTAN MODEN
published on 2024-10-08


Additional Indications Approved
published on 2024-10-08


Data Exclusivity
published on 2024-10-04


Kenyataan Media KKM 02 Oktober 2024- Makluman Produk-Produk Kosmetik yang Dikesan Mengandungi Racun Berjadual
published on 2024-10-02


Kenyataan Media KKM 30 September 2024- Makluman Produk-Produk Kosmetik yang Dikesan Mengandungi Racun Berjadual
published on 2024-10-01


Fluconazole: Updates on the Known Risk of Spontaneous Abortion During Pregnancy and Congenital Malformations in Children Exposed to Fluconazole in Utero
published on 2024-10-01


Pseudoephedrine: Risk of Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS)
published on 2024-09-30


Prosedur dan Kriteria Pelanjutan Tempoh Sah Pusat Kajian Bioekuivalens (BE) dan Jawatankuasa Etika yang berdaftar dengan Pihak Berkuasa Kawalan Dadah (PBKD)
published on 2024-09-19


Penerbitan Garis Panduan Malaysian Guideline For Bioequivalence Inspection Edisi Kedua
published on 2024-09-19


Safety Signal Alert: Mefenamic Acid-Associated Generalised Bullous Fixed Drug Eruption (GBFDE)
published on 2024-09-02


Garis Panduan Penilaian Kesetaraan Taraf Amalan Perkilangan Baik (APB) Pengilang TMHS Luar Negara, Edisi Pertama, September 2024
published on 2024-08-30


Progestogens (Cyproterone Acetate, Medroxyprogesterone Acetate, Chlormadinone): Risk of Meningioma
published on 2024-08-25


[Updated August 2024] Product Classification Form - NPRA/413/01-3
published on 2024-08-20


Pengemaskinian Drug Registration Guidance Document (DRGD) Berkaitan Keperluan Deklarasi Bahan Bersumberkan Haiwan Pada Label Produk
published on 2024-08-14


Azacitidine (Injectable Formulation): Risk of Cutaneous Vasculitis
published on 2024-08-12


Deficiency Analysis in On-Site Good Manufacturing Practice (GMP) Inspections of Manufacturers for Medicinal Products and Cosmetics by National Pharmaceutical Regulatory Agency (NPRA)
published on 2024-07-24


Direktif untuk penggunaan Drug Registration Guidance Document (DRGD) Third Edition, Eighth Revision July 2024
published on 2024-07-23


17-Hydroxyprogesterone Caproate (17-OHPC): Potential Cancer Risk in Offspring Exposed in Utero and Limited Efficacy Data
published on 2024-07-19


Pre-Membership Module Announcement
published on 2024-07-18


Hydroxychloroquine: Risk of Sweet’s Syndrome (Acute Febrile Neutrophilic Dermatosis)
published on 2024-07-15


Direktif untuk semua produk yang mengandungi Hydroxychloroquine : Pengemaskinian sisip bungkusan dan Risalah Maklumat Ubat Untuk Pengguna (RiMUP) dengan maklumat keselamatan berkaitan risiko Acute Febrile Neutrophilic Dermatosis (Sweet’s Syndrome)
published on 2024-07-11


Direktif untuk semua produk yang mengandungi Azacitidine (sediaan injeksi sahaja) : Pengemaskinian sisip bungkusan dengan maklumat keselamatan berkaitan risiko Cutaneous Vasculitis
published on 2024-07-11


Pertandingan Perarakan (Parade) sempena Majlis Perasmian Sambutan Ulang Tahun Bandaraya Petaling Jaya ke-18 dan Pra-Pelancaran Petaling Jaya International Folklore Festival 2025
published on 2024-07-10


Anti-Clusters of Differentiation 20 (CD20) Antibodies (Rituximab, Obinutuzumab, Ofatumumab, Ocrelizumab): Risk of Pyoderma Gangrenosum
published on 2024-06-28


PEKELILING BIL 2/2024 MAKLUMAN BERKENAAN STATUS KEMASKINI BAHAN-BAHAN DALAM ANNEX PADA GUIDELINES FOR CONTROL OF COSMETIC PRODUCTS IN MALAYSIA
published on 2024-06-19


Orphan Medicines Approved
published on 2024-06-11


Garis Panduan Persediaan Pemeriksaan APB Bagi Pengilang Pengilang Tradisional, Suplemen Kesihatan dan Kosmetik, Edisi Keempat, Jun 2024
published on 2024-05-31


Guidance Document For Preparation of Good Manufacturing Practice (GMP) Inspections On Traditional Medicines, Health Supplements and Cosmetics Manufacturers, Fourth Edition, June 2024
published on 2024-05-30


Amoxicillin: Risk of Aseptic Meningitis
published on 2024-05-29


Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors (Dapagliflozin, Empagliflozin, Canagliflozin): Interaction with Lithium (for Therapeutic Use) Leading to Decreased Serum Lithium Concentration
published on 2024-05-28


Guideline on Electronic Labelling (E-Labelling) For Pharmaceutical Products in Malaysia
published on 2024-05-21


[Updated] Olmesartan: Risk of Autoimmune Hepatitis
published on 2024-05-06


Proton Pump Inhibitors: Risk of Erectile Dysfunction
published on 2024-04-30


Levetiracetam and Clobazam: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
published on 2024-04-29


Hydrochlorothiazide: Risk of Acute Respiratory Distress Syndrome (ARDS)
published on 2024-04-18


Ciprofloxacin, Moxifloxacin, Levofloxacin and Ofloxacin (Fluoroquinolones) for Systemic Use (Oral and Injection): Risk of Suicidal Behaviours
published on 2024-04-17


Direktif untuk semua produk yang mengandungi hydrochlorothiazide (termasuk produk kombinasi): Pengemaskinian sisip bungkusan dan Risalah Maklumat Ubat Untuk Pengguna (RIMUP) dengan maklumat keselamatan berkaitan risiko Acute Respiratory Distress Syndrome (ARDS)
published on 2024-04-16


Direktif untuk semua produk yang mengandungi olmesartan (termasuk produk kombinasi): Pengemaskinian sisip bungkusan dan Risalah Maklumat Ubat Untuk Pengguna (RIMUP) dengan maklumat keselamatan berkaitan risiko hepatitis autoimun (autoimmune hepatitis)
published on 2024-04-16


Direktif untuk semua produk yang mengandungi Mefenamic Acid: Pengemaskinian Sisip Bungkusan dan Risalah Maklumat Ubat Untuk Pengguna (RiMUP) dengan maklumat keselamatan berkaitan Generalised Bullous Fixed Drug Eruption (GBFDE)
published on 2024-04-16


Direktif untuk semua produk yang mengandungi ciprofloxacin, moxifloxacin, levofloxacin dan ofloxacin untuk kegunaan sistemik (sediaan oral dan injeksi) : Pengemaskinian sisip bungkusan dan Risalah Maklumat Ubat Untuk Pengguna (RIMUP) dengan maklumat keselamatan berkaitan risiko suicidal behaviour
published on 2024-04-16


Direktif untuk semua produk yang mengandungi dapagliflozin, empagliflozin, canagliflozin (termasuk produk kombinasi) dan lithium (untuk tujuan rawatan) : Pengemaskinian sisip bungkusan dan Risalah Maklumat Ubat Untuk Pengguna (RIMUP) dengan maklumat keselamatan berkaitan risiko penurunan paras serum lithium akibat interaksi ubat
published on 2024-04-16


Direktif berkenaan pendaftaran produk semula jadi berdasarkan Guideline on Natural Products with Modern Claim
published on 2024-04-15


Makluman Penambahbaikan Proses Pengeluaran Lesen Mengimport / Lesen Pemborong melalui Penilaian dan Pemeriksaan Pra-Pelesenan
published on 2024-04-05


Information Sharing Paper for Cosmetic Products in the 37th ASEAN Cosmetic Committee Meeting (8-9th May 2023)
published on 2024-03-27


Guidelines for Clinical Trial
published on 2024-03-20


Direktif Berkenaan Pengemaskinian Garis Panduan Malaysian Guideline For Application Of Clinical Trial Import Licence (CTIL) And Clinical Trial Exemption (CTX)
published on 2024-03-19


Iklan Sebut Harga Kerja-Kerja Menaiktaraf Sistem Pendingin Hawa Di Program Perkhidmatan Farmasi, Ibu Pejabat Kementerian Kesihatan Malaysia
published on 2024-03-15


Domperidone: Risk of Psychiatric Withdrawal Events When Used Off-Label for Lactation Stimulation
published on 2024-03-12


Senarai Produk Tidak Berdaftar/Berdaftar Tetapi Tidak Dipasarkan Dengan Bilangan Permohonan Ubat Kelulusan Khas (UKK) Tertinggi Bagi Tahun 2023
published on 2024-03-11


[Updated] Metformin: Risk of Vitamin B12 Deficiency
published on 2024-03-04


Direktif berkenaan pelaksanaan Electronic Labelling (e-Labelling) ke atas produk farmaseutikal di Malaysia
published on 2024-02-22


Direktif berkenaan pindaan kepada proses meluluskan permohonan Lesen Import Percubaan Klinikal (CTIL) dan Kebenaran Untuk Mengilang Produk Tidak Berdaftar Untuk Tujuan Percubaan Klinikal (CTX) yang melibatkan kajian klinikal First-in-Human (FIH).
published on 2024-02-20


Direktif Berkenaan Pengemaskinian dan Pelaksanaan Guideline for Facilitated Registration Pathway (FRP), Revision 1, 2023
published on 2024-02-19


Pekeliling Berkenaan Pengemaskinian Guidance Document and Guidelines for Registration of Biosimilars in Malaysia
published on 2024-02-19


Guidance Document and Guidelines for Registration of Biosimilars in Malaysia
published on 2024-02-19


Guideline For Facilitated Registration Pathway (FRP)
published on 2024-02-17


Statins (Atorvastatin, Rosuvastatin, Simvastatin): Interaction with Ticagrelor Leading to Increased Risk of Rhabdomyolysis
published on 2024-02-15


Keputusan Mesyuarat Pihak Berkuasa Kawalan Dadah Kali Ke-393
published on 2024-02-09


Rejection of BE Studies Conducted at the BE Centre Synapse Labs Pvt. Ltd., India following Inspection Findings by The European Medicines Agency (EMA)
published on 2024-01-23


Makluman Pengemaskinian Tempoh Jangka Hayat Vaksin COVID-19 iaitu CoronaVac Daripada 30 Bulan Kepada 36 Bulan
published on 2024-01-23


Penolakan Kajian Bioekuivalens (BE) yang Dijalankan oleh Pusat Kajian BE Synapse Labs Pvt. Ltd. Susulan Penemuan Pemeriksaan European Medicines Agency (EMA)
published on 2024-01-23


Imatinib: Risk of Thrombotic Microangiopathy
published on 2024-01-22


PEKELILING BIL 1/2024 MAKLUMAN BERKENAAN STATUS KEMASKINI BAHAN-BAHAN DALAM ANNEX PADA GUIDELINES FOR CONTROL OF COSMETIC PRODUCTS IN MALAYSIA
published on 2024-01-19


Direktif untuk penggunaan Drug Registration Guidance Document (DRGD) Third Edition, Seventh Revision January 2024
published on 2024-01-19


Rivastigmine: Risks of QT Prolongation and Torsade de Pointes
published on 2024-01-19


Pekeliling berkenaan pengemaskinian syarat pendaftaran midazolam dalam Drug Registration Guidance Document (DRGD)
published on 2024-01-18


Direktif untuk semua produk yang mengandungi rivastigmine: Pengemaskinian sisip bungkusan dan Risalah Maklumat Ubat Untuk Pengguna (RIMUP) dengan maklumat keselamatan berkaitan risiko QT prolongation dan Torsade de Pointes (TdP)
published on 2024-01-18


Direktif untuk semua produk yang mengandungi imatinib: Pengemaskinian sisip bungkusan dan Risalah Maklumat Ubat Untuk Pengguna (RIMUP) dengan maklumat keselamatan berkaitan risiko thrombotic microangiopathy (TMA)
published on 2024-01-18


Direktif untuk semua produk yang mengandungi metformin (termasuk produk kombinasi): Pengemaskinian sisip bungkusan dan Risalah Maklumat Ubat Untuk Pengguna (RIMUP) bagi memperkukuhkan maklumat keselamatan berkaitan risiko kekurangan vitamin B12 (vitamin B12 deficiency)
published on 2024-01-17


New Drug Products (NCE)
published on 2023-12-26


DCA News
published on 2023-12-20


Pekeliling Berkenaan Pengemaskinian Guidance Document and Guidelines for Registration of Biosimilars in Malaysia
published on 2023-12-18


Clomiphene: Risk of Serious Visual Disturbances Potentially Leading to Blindness
published on 2023-12-01


Ibrutinib (IMBRUVICA®): Package Insert Updates to Dose Modifications for Adverse Reactions and to Special Warnings and Precautions for Use
published on 2023-11-29


[Updated] Loperamide: Risk of Acute Pancreatitis
published on 2023-11-29


[Updated] Topiramate: Neurodevelopmental Disorders in Children Exposed to Topiramate during Pregnancy
published on 2023-11-28


Thanks for Joining #MedSafetyWeek 2023 💖
published on 2023-11-11


Hi! Are You a Nurse? 🏥
published on 2023-11-10


Approved Clinical Trial Import License & Clinical Trial Exemption (CTX) Application
published on 2023-11-10


Hey, Are You a Doctor? 👨‍⚕️🏥👩‍⚕️
published on 2023-11-09


Concerned About Side Effects? Remember to check 👀 , talk 🗣 , and tell 💬 this #MedSafetyWeek!
published on 2023-11-08


💊 Medications in Malaysia are Continually Monitored to Ensure Their Safety 🔎
published on 2023-11-07


Sleep Troubles After Medication 😵? Remember to Report Them 📝
published on 2023-11-06


Unexpected Side Effects Can Happen Anywhere, at Any Time: Your Report, Patients' Safety 💊
published on 2023-11-06


📣 #MedSafetyWeek kicks off today!
published on 2023-11-05


Preparations for #MedSafetyWeek are well underway – are you ready?
published on 2023-11-03


Get Ready for #MedSafetyWeek 2023!
published on 2023-11-01


Direktif untuk penggunaan Drug Registration Guidance Document (DRGD) Third Edition, Sixth Revision October 2023
published on 2023-10-24


Isotretinoin: Risk of Psychiatric Disorders and Sexual Dysfunction
published on 2023-10-13


Direktif untuk semua produk yang mengandungi topiramate: Pengemaskinian sisip bungkusan dan Risalah Maklumat Ubat Untuk Pengguna (RiMUP) dengan maklumat keselamatan berkaitan risiko gangguan neurodevelopmental dalam kalangan kanak-kanak yang terdedah kepada topiramate semasa kehamilan ibu dan menyelaraskan maklumat keselamatan berkenaan risiko kecacatan kongenital (congenital malformation)
published on 2023-10-13


Direktif untuk semua produk yang mengandungi loperamide : Pengemaskinian sisip bungkusan dan Risalah Maklumat Ubat Untuk Pengguna (RiMUP) dengan maklumat keselamatan berkaitan risiko pankreatitis akut (acute pancreatitis)
published on 2023-10-13


Senarai Produk Tidak Berdaftar/Berdaftar Tetapi Tidak Dipasarkan Dengan Bilangan Permohonan Ubat Kelulusan Khas (UKK) Tertinggi Bagi Tahun 2022
published on 2023-09-08


Cephalosporins: Risk of Seizures
published on 2023-09-05


 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Friday 01 November 2024, 09:13:24.

Search

Main Menu English

Industry Menu